TWI901581B - 靶向C5aR的抗體 - Google Patents

靶向C5aR的抗體

Info

Publication number
TWI901581B
TWI901581B TW109108367A TW109108367A TWI901581B TW I901581 B TWI901581 B TW I901581B TW 109108367 A TW109108367 A TW 109108367A TW 109108367 A TW109108367 A TW 109108367A TW I901581 B TWI901581 B TW I901581B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
region
human
c5ar
Prior art date
Application number
TW109108367A
Other languages
English (en)
Chinese (zh)
Other versions
TW202041535A (zh
Inventor
茱麗亞 諾伊格鮑爾
科內茨基 芭芭拉 巴赫勒
坦賈 赫爾曼
溫弗里德 伊里斯
Original Assignee
德商莫菲西斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商莫菲西斯公司 filed Critical 德商莫菲西斯公司
Publication of TW202041535A publication Critical patent/TW202041535A/zh
Application granted granted Critical
Publication of TWI901581B publication Critical patent/TWI901581B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW109108367A 2019-03-14 2020-03-13 靶向C5aR的抗體 TWI901581B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19162759 2019-03-14
EP19162759 2019-03-14

Publications (2)

Publication Number Publication Date
TW202041535A TW202041535A (zh) 2020-11-16
TWI901581B true TWI901581B (zh) 2025-10-21

Family

ID=65812165

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109108367A TWI901581B (zh) 2019-03-14 2020-03-13 靶向C5aR的抗體

Country Status (14)

Country Link
US (3) US20220135658A1 (enExample)
EP (1) EP3938393A1 (enExample)
JP (2) JP7617012B2 (enExample)
KR (1) KR102977518B1 (enExample)
CN (1) CN113574072B (enExample)
AU (1) AU2020235263B2 (enExample)
BR (1) BR112021017860A2 (enExample)
CA (1) CA3132771A1 (enExample)
IL (1) IL286238A (enExample)
MA (1) MA55285A (enExample)
MX (1) MX2021011040A (enExample)
SG (1) SG11202108761YA (enExample)
TW (1) TWI901581B (enExample)
WO (1) WO2020182974A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2022057910A1 (en) * 2020-09-17 2022-03-24 I-Mab Biopharma Co., Ltd Combination therapies targeting c5ar and pd-1/pd-l1 pathways
US11912781B2 (en) * 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201311724A (zh) * 2011-06-06 2013-03-16 Novo Nordisk As 治療性抗體

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US8071096B2 (en) * 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101559599B1 (ko) * 2007-11-26 2015-10-12 바이엘 인텔렉쳐 프로퍼티 게엠베하 항-메소텔린 항체 및 이의 용도
CA2714296A1 (en) * 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies
AU2011245117B2 (en) * 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
DK2994488T3 (da) * 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister
ES2736500T3 (es) 2014-06-18 2020-01-02 Morphosys Ag Proteínas de fusión y usos de las mismas
AU2018286754A1 (en) * 2017-06-23 2019-12-19 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201311724A (zh) * 2011-06-06 2013-03-16 Novo Nordisk As 治療性抗體

Also Published As

Publication number Publication date
US12018072B2 (en) 2024-06-25
JP2025069140A (ja) 2025-04-30
JP7842914B2 (ja) 2026-04-08
WO2020182974A1 (en) 2020-09-17
AU2020235263B2 (en) 2026-06-04
EP3938393A1 (en) 2022-01-19
US20220135658A1 (en) 2022-05-05
TW202041535A (zh) 2020-11-16
MA55285A (fr) 2022-01-19
US20240400657A1 (en) 2024-12-05
AU2020235263A1 (en) 2021-09-02
JP7617012B2 (ja) 2025-01-17
SG11202108761YA (en) 2021-09-29
BR112021017860A2 (pt) 2021-12-07
KR102977518B1 (ko) 2026-06-12
KR20210141988A (ko) 2021-11-23
US20240018225A1 (en) 2024-01-18
MX2021011040A (es) 2021-12-10
NZ778810A (en) 2025-10-31
JP2022524449A (ja) 2022-05-02
CN113574072A (zh) 2021-10-29
CN113574072B (zh) 2023-12-12
IL286238A (en) 2021-10-31
CA3132771A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
US12410256B2 (en) Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
AU2015341884B2 (en) CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
JP2023162190A (ja) 抗ｓｉｒｐａ抗体およびその使用法
KR102257154B1 (ko) Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
US12304957B2 (en) Anti-CD161 antibodies and uses thereof
WO2018089508A2 (en) Anti-cd47 antibodies
AU2016364891A1 (en) Anti-OX40 antibodies and methods of use thereof
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
KR20190002644A (ko) FcγRIIA에 특이적인 결합 분자 및 이의 용도
WO2019184935A1 (zh) 抗cd27抗体、其抗原结合片段及其医药用途
JP2021513328A (ja) 抗ｍｓ４ａ６ａ抗体及びその使用方法
RU2823245C2 (ru) Антитела, нацеливающиеся на C5aR
HK40061359B (en) Antibodies targeting c5ar
HK40061359A (en) Antibodies targeting c5ar